Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor
AssigneeGenentech, Inc.
InventorCharles E. EIGENBROT, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.
Claims59
A crystal comprising a human hepatocyte growth factor activator (HGFA) comprising SEQ ID NO:1, or a fragment of SEQ ID NO:1 comprising the sequence of amino acids 373 to 655 of SEQ ID NO:1.
(canceled)
(canceled)
A molecule or molecular complex comprising at least a portion of an unbound HGFA binding site of a polypeptide having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting of 489(95), 537(138), 559(160), 573(172), 576(175), 577(176), 581(180), 591(188), 592 (189), 593(190), 616(213), 617(214), 618(215), 619(216), 620(217), 621(219), 622(220), 626(223), 627(224), 628(225), 629(226), 630(227), 631(228), and mixtures thereof, and the at least one amino acid residue is defined by a set of points having a root mean square deviation of less than about 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structure coordinates listed in Table 7.
(canceled)
A three-dimensional configuration of points displayed as a holographic image, a stereodiagram, a model, or a computer-displayed image, at least a portion of the points derived from structure coordinates listed in Table 7, comprising a HGFA binding site, wherein the HGFA domain forms a crystal having the space group symmetry P21.
A machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein a machine programmed with instructions for using such data displays a graphical three-dimensional representation of at least one molecule or molecular complex comprising at least a portion of a HGFA binding site, the binding site defined by a set of points having a root mean square deviation of less than about 0.05 Å from points representing the atoms of the amino acids as represented by the structure coordinates listed in Table 7 or 8.
A machine readable data storage medium comprising data storage material encoded with a first set of machine readable data which is combined with a second set of machine readable data using a machine programmed with instructions for using the first and second sets of data, and which determines at least a portion of the structure coordinates corresponding to the second set of data, wherein the first set of data comprises a Fourier transform of at least a portion of the HGFA structural coordinates of Table 7 or 8, and wherein the second set of data comprises an X-ray diffraction pattern of a molecule or molecular complex for which the three dimensional structure is unknown or incompletely known.
A molecule or molecular complex comprising at least a portion of a HGFA binding site for an inhibitor or substrate having an amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue in a position of HGFA in a S1, S2, S3/4, S1′, S2′, S3′ subsite, or mixtures thereof, and the at least one amino acid residue is defined by a set of points have a root mean square deviation of less than 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structural coordinates listed in Table 8.
A molecule or molecular complex comprising at least a portion of a HGFA binding site for a substrate or inhibitor comprising a sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting of 427(35), 430(40), 431(41), 432(42), 447(57), 448(58), 449(59), 451(60a), 492(98), 493(99a), 494(99), 497 (102), 542(143), 550 (151), 576 (175), 581(180), 592(189), 593(190), 594(191), 595(192), 596(193), 597(194), 598(195), 616(213), 618(215), 619(216), 621(219), 622(220), 631(228), and mixtures thereof, and the at least one amino acid residue is defined by a set of points having a mean square deviation of less than about 0.70 Å from points representing the backbone atoms of the amino acids as represented by the structure coordinates listed in Table 8.
23-24. (canceled)
A method for obtaining structural information about a molecule or molecular complex comprising application of at least a portion of the HGFA structure coordinates listed in Table 7 or 8 to an X-ray diffraction pattern of the molecule or molecular complex's crystal structure to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
A computer-assisted method for identifying an agent that modulates HGFA activity comprising:
- (a) providing a computer modeling application with a set of structure coordinates of Table 7 or 8 defining at least a portion of a HGFA binding site;
- (b) providing the computer modeling application with a set of structure coordinates for a test agent;
- and
- (c) modeling the structure of (a) complexed with (b) to determine if the test agent associates with the HGFA binding site.
A computer-assisted method for designing an agent that binds the HGFA binding site, comprising:
- (a) providing a computer modeling application with a set of structural coordinates of Table 7 or 8 defining at least a portion of the HGFA binding site;
- and
- (b) modeling the structural coordinates of (a) to identify an agent that contacts at least one amino acid residue in the HGFA binding site.
A method of identifying a molecule that mimics HGFA comprising:
- a) searching a molecular structure database with the structural coordinates of Table 7 or 8;
- and
- b) selecting a molecule from the database that mimics the structural coordinates of the HGFA.
A method of assessing agents that are antagonists or agonists of HGFA comprising:
- a) applying at least a portion of the crystallography coordinates of Table 7 or 8 to a computer algorithm that generates a 3 dimensional model of HGFA suitable for designing molecules that are antagonists or agonists;
- and
- b) searching a molecular structure database to identify potential antagonists or agonists of HGFA.
(canceled)
A method for evaluating the ability of a chemical agent to associate with a molecule or molecular complex comprising at least one amino acid residue in a subsite of HGFA binding site selected from the group consisting of S1, S2, S3/4, S1′, S2′, S3′, and mixtures thereof, said method comprising employing computational means to perform a fitting operation between the chemical agent and the structure coordinates of the amino acid residues of the binding site;
- and analyzing the results of the fitting operation and selecting those chemical agents that associate with the amino acid residue as defined by favorable polar, nonpolar, electrostatic, shape complementarity, or combinations thereof after conformational adjustments to the binding site.
(canceled)
A peptide consisting of an amino acid sequence starting at position 256 and ending at position 284 of a polypeptide having a sequence of SEQ ID NO:3 or SEQ ID NO:4.
A three-dimensional configuration of points, at least a portion of the points derived from structure coordinates listed in Table 8, comprising a HGFA binding site for an inhibitor, wherein the HGFA forms a crystal having the space group symmetry P3121.
A machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein a machine programmed with instructions for using such data displays a graphical three-dimensional representation of at least one molecule or molecular complex comprising at least a portion of a HGFA binding site or or an inhibitor or substrate, the binding site defined by a set of points having a root mean square deviation of less than about 0.05 Å from points representing the atoms of the amino acids as represented by the structure coordinates listed in Table 8.
A crystal of hepatocyte growth factor activator (HGFA) complexed with a Kunitz domain inhibitor comprising a human hepatocyte growth factor activator comprising SEQ ID NO:2 complexed with a Kunitz domain inhibitor comprising SEQ ID NO:4.
(canceled)
(canceled)
A computer assisted method for identifying an agent that modulates HGFA activity comprising:
- a) modifying of at least one amino acid residue in a HGFA binding site on a Kunitz domain inhibitor;
- b) performing a fitting operation between the modified Kunitz domain inhibitor and the structural coordinates of at least one amino acid residue of a HGFA binding site for KD1 as set forth in Table 8.
A method of inhibiting HGFA in a cell comprising contacting the cell with a fragment of a Kunitz domain inhibitor comprising an amino acid sequence corresponding to amino acid sequence of amino acid 256 to 284 of a polypeptide having a sequence of SEQ ID NO:3, SEQ ID NO:4, an amino acid sequence Val-Arg-Cys-Arg-Xaa-Ser-Phe (SEQ ID NO:5), wherein Xaa is Gly, Ala, or Ser, or an amino acid sequence Val-Gly-Arg-Cys-Arg-Xaa-Ser-Phe, wherein Xaa is Gly, Ala, or Ser (SEQ ID NO:8).
A fragment of HGFA comprising an amino acid sequence starting from any amino acid located at position 373 to amino acid 408 and ending at amino acid residue 655.
A fragment of a Kunitz domain inhibitor comprising an amino acid sequence of SEQ ID NO:4.
A peptide inhibitor of HGFA comprising an amino acid sequence Val-Arg-Cys-Arg-Xaa-Ser-Phe (SEQ ID NO:5).
A molecule or molecular complex comprising at least a portion of a HGFA binding site for an inhibitor, wherein HGFA comprises a sequence of SEQ ID NO:1 or SEQ ID NO:2, wherein the binding site comprises at least one amino acid residue corresponding to an amino acid residue in a position of HGFA selected from the group consisting His447(57), Ser450(60), His451(60a), Pro493(99a), Ser494(99), Asp497(102), Asp592(189), Ala593(190), Cys594(191), Gln595(192), Ser598(195), Ile616(213), Ser617(214), Trp618(215), Gly619(216), Asp620(217), Gly621(219), Cys622(220), Gly629(226), and mixtures thereof, wherein the at least one amino acid residue is defined by a set of points having a root mean sequence deviation of about 0.70 Å or less from points representing the backbone of the amino acids as represented by the structural coordinates in Table 8.
Dependencies are inferred from the claim text.